Variable Non-Metformin user Metformin user Overall P value
Number 368 (90%) 41 (10%) 409 (100%)  
Age(Mean±SD); Range 68.3±10.3; 21-93 71.0±8.8; 45-85 68.5±10.2; 21-93 0.131
Gender-Male 157 (42.7%) 15 (36.6%) 172 (42.1%) 0.455
Race White Others 340 (92.4%) 28 (7.6%) 35 (85.4%) 6 (14.6%) 375 (91.7%) 34 (8.3%) 0.122
Smoking Current Previous Never 157 (42.7%) 179 (48.6%) 32 (8.7%) 12 (29.3%) 24 (58.5%) 5 (12.2%) 169 (41.3%) 203 (49.6%) 37 (9%) 0.243
Surgery Lobectomy Pneumonectomy 360 (97.8%) 8 (2.2%) 41 (100%) 0 (0%) 401 (98%) 8 (2.0%) 0.688
Histology Adenocarcinoma SqCC Others 224 (60.9%) 108 (29.3%) 36 (9.8%) 20 (48.8%) 16 (39%) 5 (12.2%) 244 (59.7%) 124 (30.3%) 41 (10%) 0.323
Pathologic stage IA IB 231 (62.8%) 137 (37.2%) 28 (68.3%) 13 (31.7%) 259 (63.3%) 150 (36.7%) 0.487
Insulin use Yes No 6 (1.6%) 362 (98.4%) 10 (24.4%) 31 (75.6%) 16 (3.9%) 393 (96%) <0.001
Alive at last follow up Yes No 223 (60.6%) 145 (39.4%) 34 (82.9%) 7 (17.1%) 257 (62.8%) 152 (37.2%) 0.005
Table 1: Patient Demographics (N=409); A significantly higher proportion of metformin users were on insulin and were alive at the last follow up. SqCC-Squamous Cell Carcinoma.